YARW
Yarrow Bioscience Inc
Price Chart
Latest Quote
$28.44
-0.67 (-2.30%)
Current Price
| Previous Close | $29.11 |
| Open | $29.98 |
| Day High | $29.98 |
| Day Low | $27.50 |
| Volume | 43,298 |
Stock Information
| Shares Outstanding | 2.67M |
| Cash Equivalents | $18.67M |
| Net Income | $-283.98M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $72.11M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $163.50M |
| Income | $-283.98M |
| Cash/sh | $6.99 |
| Employees | 7 |
Financial Ratios
| Quick Ratio | 1.40 |
| Current Ratio | 1.40 |
Returns & Margins
Ownership
| Insider Ownership | 7.12% |
| Institutional Ownership | 66.69% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -16.37 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $57.00 |
Technical Indicators
| SMA20 | $35.04 |
| SMA50 | $31.18 |
| SMA200 | $20.26 |
| RSI | 25.30 |
| ATR | 3.8439 |
| Shares Float | 1.75M |
| Short Ratio | 1.72 |
| Volatility | 2.07 |
| Rel Volume | 12.72 |
Performance History
| Week | -6.38% |
| Month | -36.85% |
| Quarter | +43.91% |
| 6 Months | +63.03% |
| YTD | +65.00% |
| Year | +211.73% |
| 3 Years | -78.30% |
| 5 Years | -96.84% |
| 10 Years | -99.95% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-09-11 | $27.01 | 1,364,900 |
| 2026-09-10 | $28.44 | 43,700 |
| 2026-09-09 | $29.11 | 36,600 |
| 2026-09-08 | $29.30 | 37,900 |
| 2026-09-04 | $30.21 | 26,600 |
| 2026-09-03 | $28.85 | 29,100 |
| 2026-09-02 | $29.98 | 34,000 |
| 2026-09-01 | $30.98 | 45,200 |
| 2026-08-31 | $32.96 | 83,100 |
| 2026-08-28 | $37.00 | 39,400 |
| 2026-08-27 | $38.00 | 37,500 |
| 2026-08-26 | $39.63 | 31,400 |
| 2026-08-25 | $39.25 | 9,300 |
| 2026-08-24 | $39.50 | 207,300 |
| 2026-08-21 | $36.42 | 26,000 |
| 2026-08-20 | $38.20 | 22,400 |
| 2026-08-19 | $40.60 | 34,100 |
| 2026-08-18 | $41.52 | 17,600 |
| 2026-08-17 | $41.40 | 14,600 |
| 2026-08-14 | $42.49 | 5,200 |
| 2026-08-13 | $42.72 | 13,600 |
| 2026-08-12 | $42.77 | 11,200 |
About Yarrow Bioscience Inc
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
đ° Latest News
No news articles available at the moment. Check back later for updates on YARW.
Period:
Loading...
Balance Sheet (Annual)
| Metric | 2025-12-31 |
|---|---|
| Assets | |
| Net Tangible Assets | $28,860,000 |
| Total Assets | $100,407,000 |
| Total Non Current Assets | $407,000 |
| Non Current Deferred Assets | $407,000 |
| Current Assets | $100,000,000 |
| Other Current Assets | $6,000 |
| Receivables | $0 |
| Cash Cash Equivalents And Short Term Investments | $99,994,000 |
| Cash And Cash Equivalents | $99,994,000 |
| Cash Financial | $99,994,000 |
| Liabilities | |
| Total Liabilities Net Minority Interest | $71,547,000 |
| Total Non Current Liabilities Net Minority Interest | $0 |
| Current Liabilities | $71,547,000 |
| Payables And Accrued Expenses | $71,547,000 |
| Payables | $1,534,000 |
| Accounts Payable | $1,534,000 |
| Equity | |
| Common Stock Equity | $-70,990,000 |
| Preferred Stock Equity | $99,850,000 |
| Total Equity Gross Minority Interest | $28,860,000 |
| Stockholders Equity | $28,860,000 |
| Retained Earnings | $-70,994,000 |
| Other | |
| Ordinary Shares Number | $2,803,078 |
| Share Issued | $2,803,078 |
| Tangible Book Value | $-70,990,000 |
| Invested Capital | $-70,990,000 |
| Working Capital | $28,453,000 |
| Total Capitalization | $28,860,000 |
| Additional Paid In Capital | $4,000 |
| Capital Stock | $99,850,000 |
| Common Stock | $0 |
| Preferred Stock | $99,850,000 |
| Current Accrued Expenses | $70,013,000 |
Fetched: 2026-08-23